Abstract

Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer’s disease.

Original languageEnglish
Article numbereadk9993
JournalScience translational medicine
Volume15
Issue number721
DOIs
StatePublished - 2023

Fingerprint

Dive into the research topics of 'Current status of amyloid-targeting immunotherapies for Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this